<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05064020</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003629</org_study_id>
    <nct_id>NCT05064020</nct_id>
  </id_info>
  <brief_title>Bictegravir in the Elderly Living With HIV (BICEP)</brief_title>
  <official_title>Bictegravir in the Elderly Living With HIV: Impact of Polypharmacy and Multimorbidity (BICEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State University of New York at Buffalo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>State University of New York at Buffalo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, single center, post-approval and post-marketing study.&#xD;
      Current national guideline recommends an integrase strand inhibitors (INSTI) in combination&#xD;
      with two nucleoside reverse transcriptase inhibitors (NRTIs) as standard of therapy for HIV-1&#xD;
      infected patients. INSTI-based regimen may require a potent CYP3A inhibitor such as&#xD;
      cobicistat to increase INSTI's plasma concentration and prolongs half-life. However,&#xD;
      co-administration with a CYP3A inhibitor may increase the risk of drug-drug interactions. A&#xD;
      novel INSTI, bictegravir, does not need a booster for pharmacokinetic enhancement.&#xD;
&#xD;
      Hypothesis: switching HIV-1 infected patients from booster containing regimen to bictegravir&#xD;
      based regimen would decrease the risk of drug-drug interactions caused by a booster and&#xD;
      improve quality of life and adherence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiretroviral treatment consisting of integrase strand inhibitors (INSTI) in combination&#xD;
      with two nucleoside reverse transcriptase inhibitors (NRTIs) has become the standard of&#xD;
      therapy for HIV-1 infected patients (2017 DHHS Guidelines). The development and advancement&#xD;
      of such therapy have resulted in improved prognosis, allowing a larger proportion of patients&#xD;
      in United States (&gt; 50%) with HIV-1 infection to be 50 years of age or older, which is&#xD;
      defined by the CDC as &quot;older adults&quot;. A novel INSTI, bictegravir (BIC), has been recently&#xD;
      approved by FDA, available in a fixed dose combination with emtricitabine (FTC) and tenofovir&#xD;
      alafenamide (TAF) as a novel single-tablet regimen (STR), BIKTARVYÂ®. Similar to other INSTI,&#xD;
      BIC prevents HIV replication by inhibiting HIV integration into the host cell. In vitro&#xD;
      studies have shown its selectivity against HIV-1 infected cells with a low cytotoxic profile.&#xD;
&#xD;
      Elvitegravir, boosted with cobicistat, is currently available as part of a single-tablet&#xD;
      formulation with FTC and TAF (GenvoyaTM) or with FTC and TDF (StribildTM). Unlike ritonavir,&#xD;
      cobicistat has no antiretroviral activity, but has potent inhibitory effects on CYP3A44.&#xD;
      Elvitegravir is primarily metabolized by CYP3A4 and its co-administration with cobicistat&#xD;
      boosts elvitegravir plasma concentration and prolongs its half-life4. Concurrent use of a&#xD;
      potent CYP3A4 inhibitor, e.g., cobicistat, with medications that are metabolized by CYP3A4&#xD;
      can significantly increase the risk of drug-drug interactions. With an increase in the&#xD;
      average survivability age of HIV-infected patients, chances of polypharmacy due to&#xD;
      multimorbidity, a term used to define the presence of two or more concurrent chronic medical&#xD;
      conditions, increases. Two studies have demonstrated that older HIV+ individuals engaged in&#xD;
      polypharmacy are more likely to experience potential drug-drug interactions (PDDI). Many&#xD;
      chronic medications such as antidepressants, HMG-CoA reductase inhibitors (statins), and&#xD;
      cardiovascular medications are metabolized by CYP3A4. Concurrent administration of these&#xD;
      medications with GenvoyaTM and StribildTMcan lead to increases in PDDI. Such interactions can&#xD;
      result in more adverse drug reactions, drug-related toxicity of narrow therapeutic index&#xD;
      drugs, and variations in the efficacy of concurrent medications. However, unlike&#xD;
      elvitegravir, BIC does not require a booster such as cobicistat for pharmacokinetic&#xD;
      enhancement. Its use can result in reductions in PDDI caused by cobicistat in adults with&#xD;
      polypharmacy. This can improve quality of life in general, adherence and can directly avoid&#xD;
      DDI-related adverse effects.&#xD;
&#xD;
      Although antiretroviral therapy (ART), when used concurrently with certain medications, has&#xD;
      an increased risk of PDDI, studies have suggested a low DDI profile of BIC. In this study,&#xD;
      such benefits of bictegravir will be assessed through the evaluation of polypharmacy, PDDI,&#xD;
      health-related quality of life, and adherence of HIV-infected subjects.&#xD;
&#xD;
      BIC/FTC/TAF related adverse drug events are possible in the study. Due to BIC's recent FDA&#xD;
      approval, a comprehensive list on the possible adverse drug events has become available.&#xD;
      Common side effects reported in clinical phase II and phase III studies include diarrhea,&#xD;
      nausea, and headache. Serious adverse events, including lactic acidosis, severe hepatomegaly&#xD;
      have been reported with nucleoside reverse transcriptase inhibitors, but are uncommon. The&#xD;
      standard regimen of BIC/FTC/TAF will be used; if a regimen change occurs, participation in&#xD;
      the study will be discontinued. Participants will be carefully screened and those with&#xD;
      pre-conditions, such as morbid obesity, hepatitis B virus, hepatitis C virus co-infection&#xD;
      will be documented in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Probability of PDDI particularly with cobicistat and concurrent medications will be assessed throughout the study.</measure>
    <time_frame>week 1 to week 24</time_frame>
    <description>From week 1 to week 24 the study will assess drug's PDDI and concurrent medications which patients are using</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health related quality of life assessments at baseline</measure>
    <time_frame>week 12 to week 24</time_frame>
    <description>To evaluate health related quality of life based on HIV Symptom Index (range 0-80, lower scores suggest better quality of life)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adherence assessment at baseline</measure>
    <time_frame>week 4, week 8, week 12 and week 24</time_frame>
    <description>Study team will keep record of every patients adherence of taking drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid panel results at baseline.</measure>
    <time_frame>week 12 and week 24</time_frame>
    <description>Lipid panel will be drawn by protocol team and be monitored closely</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure level at baseline</measure>
    <time_frame>week 12 and week 24</time_frame>
    <description>Blood pressure will be drawn by protocol team and be monitored closely</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose level at baseline</measure>
    <time_frame>week 12 and week 24</time_frame>
    <description>Blood glucose will be drawn by protocol team and be monitored closely</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Polypharmacy</arm_group_label>
    <description>Polypharmacy: patient is using five or more medications will be considered polypharmacy.&#xD;
Subjects having polypharmacy condition with taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonpolypharmacy</arm_group_label>
    <description>Nonpolypharmacy: patient is using less than five medications will be considered nonpolypharmacy&#xD;
Nonpolypharmacy Subjects taking Elvitegravir/Cobicistat/Emtricitabine/Tenofovir/Alafenamide 150MG-150MG-200MG-10MG Oral Tablet [Genvoya] or Elevitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150MG-150MG-200MG-300MG Oral Tablet [Stribild] will switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]</intervention_name>
    <description>Administer BIC/FTC/TAF 50/200/25 mg tablet by mouth once a day from day 1 to168.</description>
    <arm_group_label>Nonpolypharmacy</arm_group_label>
    <arm_group_label>Polypharmacy</arm_group_label>
    <other_name>Biktarvy</other_name>
    <other_name>BIC/FTC/TAF</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult individuals &gt; 18 years of age with HIV-1, currently on antiretroviral therapy,&#xD;
        Genvoya or Stribild, at least 1 or more concurrent prescription medication and HIV viral&#xD;
        load &lt; 50 c/ml for over 6 months, no current OI, no cancers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult individuals &gt; 18 years of age.&#xD;
&#xD;
          -  Able and willing to provide informed/signed consent.&#xD;
&#xD;
          -  Presence of HIV-1 infection as documented by a licensed ELISA test kit and confirmed&#xD;
             by Western blot or HIV RNA.&#xD;
&#xD;
          -  Current antiretroviral therapy, Genvoya or Stribild for HIV-1 infection.&#xD;
&#xD;
          -  At least 1 or more concurrent prescription medication.&#xD;
&#xD;
          -  HIV VL &lt; 50 for over 6 months, no current OI, no cancers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of drugs of abuse or alcohol which would interfere with adherence or completion of&#xD;
             this study.&#xD;
&#xD;
          -  Current antiretroviral therapy other than GenvoyaTM or StribildTM for HIV-1 infection.&#xD;
&#xD;
          -  Pregnancy or breast-feeding. Women of childbearing potential must have a negative&#xD;
             serum or urine pregnancy test within 14 days prior to study entry and day of entry.&#xD;
&#xD;
          -  Chronic, severe, or other medical conditions that, in the opinion of the investigator,&#xD;
             would interfere with the subject's ability to participate in the protocol.&#xD;
&#xD;
          -  Use of prohibited protocol-specified drugs, prescription or over-the-counter&#xD;
             medication (see Section 6.4.2) within 14 days prior to study entry.&#xD;
&#xD;
          -  Moderate or severe cognitive impairment by history that, in the opinion of the&#xD;
             investigator, would interfere with the subject's ability to participate in the&#xD;
             protocol&#xD;
&#xD;
          -  Laboratory parameters documented within 21 days prior to study entry that would&#xD;
             increase the risk for adverse events:&#xD;
&#xD;
               1. Hemoglobin &lt; 12.5 g/dL for men; &lt; 11.5 g/dL for women;&#xD;
&#xD;
               2. Platelet count &lt; 100,000 platelets/mm 3;&#xD;
&#xD;
               3. AST (SGOT) or ALT (SGPT) &gt; 1.5 x the upper limit of normal (ULN);&#xD;
&#xD;
               4. Estimated GFR &lt; 30 ml/min&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qing Ma, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University at Buffalo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qing Ma, PharmD, PhD</last_name>
    <phone>716-881-7500</phone>
    <email>qingma@buffalo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alyssa S Shon, MD</last_name>
    <phone>716-847-2441</phone>
    <email>alyssash@buffalo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Evergreen Health</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sibu Nair</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.natap.org/2017/IAS/IAS_39.htm</url>
    <description>The link to the Citation that didn't find a PubMed ID</description>
  </link>
  <link>
    <url>http://www.biktarvyhcp.com/about-biktarvy</url>
    <description>The information related to Biktarvy package insert</description>
  </link>
  <reference>
    <citation>Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.</citation>
    <PMID>28867497</PMID>
  </reference>
  <reference>
    <citation>Gleason LJ, Luque AE, Shah K. Polypharmacy in the HIV-infected older adult population. Clin Interv Aging. 2013;8:749-63. doi: 10.2147/CIA.S37738. Epub 2013 Jun 21. Review.</citation>
    <PMID>23818773</PMID>
  </reference>
  <reference>
    <citation>Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, Niedziela-Majka A, Yant SR, Yu H, Kukolj G, Cihlar T, Lazerwith SE, White KL, Jin H. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. Print 2016 Dec.</citation>
    <PMID>27645238</PMID>
  </reference>
  <reference>
    <citation>Tseng A, Hughes CA, Wu J, Seet J, Phillips EJ. Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences. Ann Pharmacother. 2017 Nov;51(11):1008-1022. doi: 10.1177/1060028017717018. Epub 2017 Jun 19. Review.</citation>
    <PMID>28627229</PMID>
  </reference>
  <reference>
    <citation>van den Akker M, Buntinx F, Metsemakers JF, Roos S, Knottnerus JA. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol. 1998 May;51(5):367-75.</citation>
    <PMID>9619963</PMID>
  </reference>
  <reference>
    <citation>Tseng A, Szadkowski L, Walmsley S, Salit I, Raboud J. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013 Nov;47(11):1429-39. doi: 10.1177/1060028013504075.</citation>
    <PMID>24285760</PMID>
  </reference>
  <reference>
    <citation>Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15.</citation>
    <PMID>28219610</PMID>
  </reference>
  <reference>
    <citation>Marzolini C, Back D, Weber R, Furrer H, Cavassini M, Calmy A, Vernazza P, Bernasconi E, Khoo S, Battegay M, Elzi L; Swiss HIV Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011 Sep;66(9):2107-11. doi: 10.1093/jac/dkr248. Epub 2011 Jun 16.</citation>
    <PMID>21680580</PMID>
  </reference>
  <reference>
    <citation>Mrus JM, Leonard AC, Yi MS, Sherman SN, Fultz SL, Justice AC, Tsevat J. Health-related quality of life in veterans and nonveterans with HIV/AIDS. J Gen Intern Med. 2006 Dec;21 Suppl 5:S39-47.</citation>
    <PMID>17083499</PMID>
  </reference>
  <reference>
    <citation>Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. Sensitivity, specificity, reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 1999 Jun 1;21(2):126-33.</citation>
    <PMID>10360804</PMID>
  </reference>
  <reference>
    <citation>Sax PE, Pozniak A, Arribas J, et al. Phase 3 randomized, controlled, clinical trial of bictegravir coformulated with FTC/TAF in a fixed-dose combination vs dolutegravir + FTC/TAF in treatment-naÃ¯ve HIV-1-positive adults: Week 48 results. International AIDS Society (IAS) Conference on HIV Science; July 23-26, 2017; Paris, France. Levin: Conference reports for National AIDS Treatment Advocacy Project (NATAP); 2017.</citation>
  </reference>
  <reference>
    <citation>Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007 Apr;41(4):674-80. Epub 2007 Mar 27.</citation>
    <PMID>17389673</PMID>
  </reference>
  <reference>
    <citation>Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med. 2010 Apr-May;18(2):45-55. Review.</citation>
    <PMID>20516524</PMID>
  </reference>
  <reference>
    <citation>Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T, Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One. 2008 Jun 25;3(6):e2516. doi: 10.1371/journal.pone.0002516.</citation>
    <PMID>18575590</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2021</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>State University of New York at Buffalo</investigator_affiliation>
    <investigator_full_name>Qing Ma, PharmD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Switch</keyword>
  <keyword>Bictegravir</keyword>
  <keyword>Drug-drug interaction</keyword>
  <keyword>Polypharmacy</keyword>
  <keyword>Elderly</keyword>
  <keyword>Adherence</keyword>
  <keyword>Quality of life</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Emtricitabine tenofovir alafenamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share de-identified IPD only.</ipd_description>
    <ipd_time_frame>The data will be summarized and presented in the conferences and scientific journals.</ipd_time_frame>
    <ipd_access_criteria>Please contact the principal investigator for an access to IPD.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 5, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT05064020/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

